Project Grant R03DE034697
- The National Institute of Dental and Craniofacial Research awarded Old Dominion University Research Foundation $933,580 on June 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to support research on immunomodulatory therapeutic approaches to improve oral cavity wound healing. The project investigates FTY720, an active biolipid that targets the sphingosine pathway to attract proregenerative immune cells and improve healing of oronasal fistulae (ONF) while reducing...
- The National Institute of General Medical Sciences awarded the University of Washington $287,219 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate metabolic reprogramming in vertebrate appendage regeneration. The research examines how animals mobilize biomolecules—nucleotides, proteins, and lipids—to regrow lost appendages, using the frog Xenopus tropicalis as a model organism. The principal investigator's central hypothesis is that...
- The National Institute of Dental and Craniofacial Research awarded The Trustees of Columbia University in the City of New York $152,166 on September 4, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to conduct research on blastema-driven craniofacial regeneration in zebrafish. The research investigates how multiple blastemas—regenerative cell clusters—coordinate to restore craniofacial joint tissues following injury. The project uses an adult zebrafish whole joint...
- The National Institute of Dental and Craniofacial Research, part of the National Institutes of Health under the Department of Health and Human Services, awarded The University of Chicago $328,000 on August 5, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop and validate a microsimulation model of oral health lifetime outcomes and resource use in older adults. The project, titled "Development and Validation of the U.S. Oral Health Microsimulation...
- The National Institute of Dental and Craniofacial Research awarded Massachusetts General Hospital $408,951 on February 15, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121, R21DE034917) to investigate photochemical tissue passivation as a treatment approach for temporomandibular joint osteoarthritis. The research applies photocrosslinking of tissue proteins—specifically collagen—through rose bengal solution and green light exposure to reduce inflammation and prevent...
- The National Institute of General Medical Sciences awarded The Mount Desert Island Biological Laboratory $422,500 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate molecular mechanisms of limb and tail regeneration in axolotls as a foundation for developing strategies for scarless tissue regeneration in humans. The research examines why axolotls regenerate limbs and tails without scarring through blastema formation, whereas mammals form...
- The National Institute of Dental and Craniofacial Research awarded the University of Illinois $273,014 on March 1, 2030, under the Oral Diseases and Disorders Research program (CFDA 93.121) to support clinician-scientist training and research on NG2/CSPG4 signaling in mandibular endochondral fracture healing. The recipient will conduct laboratory experimentation and professional development to advance understanding of how mechanical loading-dependent NG2/CSPG4 signaling regulates the...
- The National Institute of Dental and Craniofacial Research awarded the University of California, Los Angeles $449,886 on March 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to support research on the regulation of early mandibular morphogenesis by the homeobox protein MSX1. The research addresses craniofacial anomalies, which are among the most common congenital conditions. Mutations in the MSX1 gene are associated with tooth agenesis, cleft palate, and...
- The National Institute of Dental and Craniofacial Research awarded The Trustees of Columbia University in the City of New York $621,950 on August 6, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate mechanisms of scar-free ligament repair in zebrafish as a model for human musculoskeletal healing. The project dissects how zebrafish regulate extracellular matrix turnover during ligament injury to achieve regenerative healing without fibrosis, with the goal...
- The National Institute of Child Health and Human Development awarded The Marine Biological Laboratory $431,112 on September 1, 2026, under the Child Health and Human Development Extramular Research program (CFDA 93.865) to investigate the role of neuropeptides in appendage regeneration. The research seeks to understand why salamanders and axolotls regenerate lost limbs, jaws, tails, and other tissues while humans retain only limited regenerative capacity. The work addresses therapeutic...
The National Institute of Dental and Craniofacial Research awarded Midwestern University $554,280 on August 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to establish Xenopus laevis tadpole tail regeneration as an in vivo model system for investigating photobiomodulation therapy (PBMT) in oral mucositis. The research addresses the mechanisms by which PBMT prevents and treats chemotherapy-induced oral mucositis by promoting wound healing and inhibiting inflammation. The work tests two hypotheses: that different combinations of PBMT parameters—including irradiance, treatment time, fluence, and wavelength—produce a biphasic regeneration response in Xenopus tails, and that PBMT initiates a unique signaling cascade dependent on reactive oxygen species (ROS) release to improve wound healing. The research plan includes irradiating Xenopus tadpole tails following amputation with varying PBMT parameter combinations to evaluate their effect on wound healing, and utilizing a transgenic Xenopus line to visualize intracellular ROS levels in vivo. The work will employ ROS inhibitors and activators to further characterize the signaling mechanisms. Performance occurs in Downers Grove, Illinois. The period of performance runs from August 1, 2026, through July 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/2/26 | ||
| Not listed | $277.1k | 7/24/26 |